Document is current
Any future updates will be listed below
-
Authors
Oaknin, Ana https://orcid.org/0000-0002-3592-7194
Gilbert, Lucy
Tinker, Anna V
Brown, Jubilee
Mathews, Cara
Press, Joshua
Sabatier, Renaud
O’Malley, David M
Samouelian, Vanessa
Boni, Valentina
Duska, Linda
Ghamande, Sharad
Ghatage, Prafull
Kristeleit, Rebecca
Leath III, Charles
Guo, Wei
Im, Ellie
Zildjian, Sybil
Han, Xinwei
Duan, Tao
Veneris, Jennifer
Pothuri, Bhavana
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02715284 at ClinicalTrials.govnct02715284 at ClinicalTrials.govDocuments that mention this clinical trial
2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial
https://doi.org/10.1136/ijgc-2022-esgo.878
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
https://doi.org/10.1136/ijgc-2022-003492
EP134/#1505 Dostarlimab monotherapy in mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer in the Korean expanded access program
https://doi.org/10.1136/ijgc-2023-igcs.230
386 Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
https://doi.org/10.1136/ijgc-2020-esgo.72
385 Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study
https://doi.org/10.1136/ijgc-2020-esgo.71
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
83 Time course of adverse events during dostarlimab treatment in patients with recurrent or advanced endometrial cancer in the garnet trial
https://doi.org/10.1136/ijgc-2021-esgo.113
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
https://doi.org/10.1007/s00280-021-04358-3
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England
https://doi.org/10.1136/ijgc-2022-004178
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study (Pre-results)
https://doi.org/10.1136/jitc-2021-003777
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Potential impact on cost-effectiveness estimates of using immature survival data: a case study based on transcatheter edge-to-edge repair (TEER) used for patients with severe mitral regurgitation at high surgical risk
https://doi.org/10.1136/bmjopen-2021-060423
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
nct03981796 at ClinicalTrials.govDocuments that mention this clinical trial
2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial
https://doi.org/10.1136/ijgc-2022-esgo.878
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
https://doi.org/10.1136/ijgc-2022-003492
386 Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
https://doi.org/10.1136/ijgc-2020-esgo.72
EP134/#1505 Dostarlimab monotherapy in mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer in the Korean expanded access program
https://doi.org/10.1136/ijgc-2023-igcs.230
385 Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study
https://doi.org/10.1136/ijgc-2020-esgo.71
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
83 Time course of adverse events during dostarlimab treatment in patients with recurrent or advanced endometrial cancer in the garnet trial
https://doi.org/10.1136/ijgc-2021-esgo.113
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
https://doi.org/10.1007/s00280-021-04358-3
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England
https://doi.org/10.1136/ijgc-2022-004178
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study (Pre-results)
https://doi.org/10.1136/jitc-2021-003777
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Potential impact on cost-effectiveness estimates of using immature survival data: a case study based on transcatheter edge-to-edge repair (TEER) used for patients with severe mitral regurgitation at high surgical risk
https://doi.org/10.1136/bmjopen-2021-060423
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
nct02715284 at ClinicalTrials.govDocuments that mention this clinical trial
Best original research presented at the 25th European Congress on Gynaecological Oncology: best of ESGO 2024
https://doi.org/10.1136/ijgc-2024-005844
Management of stage III and IVa uterine cancer
https://doi.org/10.1136/ijgc-2021-002554
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
https://doi.org/10.1136/ijgc-2022-003990
Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.
https://doi.org/10.1200/op.2023.19.11_suppl.332
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
1424 Treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status among patients with primary advanced or recurrent endometrial cancer (pA/rEC) in the United States
https://doi.org/10.1136/jitc-2023-sitc2023.1424
Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study
https://doi.org/10.1136/bmjopen-2023-083540
#540 Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
https://doi.org/10.1136/ijgc-2023-esgo.16
Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.5607
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
https://doi.org/10.1200/jco.2023.41.16_suppl.5503
Endometrial carcinosarcoma
https://doi.org/10.1136/ijgc-2022-004073
PR038/#248 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
https://doi.org/10.1136/ijgc-2023-igcs.80
387 ENGOT-EN6/GOG-3031/NSGO-RUBY: a phase 3, randomised, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC)
https://doi.org/10.1136/ijgc-2020-esgo.197
Advances in the management of endometrial cancer
https://doi.org/10.1136/bmj-2024-080978
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
https://doi.org/10.1136/ijgc-2024-005484
589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer
https://doi.org/10.1136/jitc-2023-sitc2023.0589
639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
https://doi.org/10.1136/ijgc-2024-esgo.34
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023
https://doi.org/10.1136/ijgc-2023-005132
625 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: analysis of progression-free survival and overall survival outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
https://doi.org/10.1136/ijgc-2024-esgo.32
633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
https://doi.org/10.1136/ijgc-2024-esgo.33
#267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial
https://doi.org/10.1136/ijgc-2023-esgo.13
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.5504
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
https://doi.org/10.1136/jitc-2021-003777
PO002/#638 Efficacy and safety of dostarlimab plus chemotherapy in patients with endometrial cancer by age category in part 1 of the ruby trial
https://doi.org/10.1136/ijgc-2024-igcs.15
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.5606
Immunotherapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003675
Biomarker-driven therapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003676
PO001/#1130 Impact of investigator-assessed response to dostarlimab on quality of life in the ruby trial of primary advanced or recurrent endometrial cancer (PA/REC)
https://doi.org/10.1136/ijgc-2024-igcs.14
Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis
https://doi.org/10.1136/ijgc-2024-005296
588 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: post hoc analysis of the costs of grade ≥3 adverse events (AEs)
https://doi.org/10.1136/jitc-2023-sitc2023.0588
462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
https://doi.org/10.1136/ijgc-2024-esgo.25
Documents that mention this clinical trial
2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial
https://doi.org/10.1136/ijgc-2022-esgo.878
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
https://doi.org/10.1136/ijgc-2022-003492
EP134/#1505 Dostarlimab monotherapy in mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer in the Korean expanded access program
https://doi.org/10.1136/ijgc-2023-igcs.230
386 Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
https://doi.org/10.1136/ijgc-2020-esgo.72
385 Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study
https://doi.org/10.1136/ijgc-2020-esgo.71
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
83 Time course of adverse events during dostarlimab treatment in patients with recurrent or advanced endometrial cancer in the garnet trial
https://doi.org/10.1136/ijgc-2021-esgo.113
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
https://doi.org/10.1007/s00280-021-04358-3
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England
https://doi.org/10.1136/ijgc-2022-004178
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study (Pre-results)
https://doi.org/10.1136/jitc-2021-003777
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Potential impact on cost-effectiveness estimates of using immature survival data: a case study based on transcatheter edge-to-edge repair (TEER) used for patients with severe mitral regurgitation at high surgical risk
https://doi.org/10.1136/bmjopen-2021-060423
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
-
Funding
Funding for this research was provided by:
GlaxoSmithKline
- License Information
